logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tisotumab vedotin for recurrent or metastatic cervical cancer

< Back

Tisotumab vedotin for recurrent or metastatic cervical cancer

Drugs

Cancer and Palliative Care

December 2019


Tisotumab vedotin is currently in clinical development for the treatment of patients with recurrent or metastatic cervical cancer who have received at least one prior systemic therapy. Cervical cancer develops in a woman’s cervix (lower part of the womb). It mainly affects sexually active women aged between 30 and 45 years. Cervical cancer often has no symptoms in its early stages. Cervical cancer that has spread to another part of the body is called advanced or metastatic cancer. Cancer that returns after months or years of the completion of the initial treatment is called recurrent cancer. The most common symptom of cervical cancer includes bleeding from the vagina at times other than the usual periods. Despite the recent developments, the prognosis remains poor and systemic therapy options are needed for women with recurrent and metastatic cervical cancer.
Tisotumab vedotin is administered by intravenous infusion. It is an antibody-drug conjugate that binds to tissue factor (TF), a protein expressed on the cell surface of tumour cells. This then induces cancer cells death. If licenced tisotumab vedotin will offer a treatment option for adult females with recurrent or metastatic cervical cancer who have received at least one prior systemic therapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts